Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance

Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market.

Shares were down 15% at 12:11 p.m. London time, shortly after the announcement.

This is a developing story. Please check back for updates.